Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ncpendmet0028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
J Nucl Med
February 2016
Department of Nuclear Medicine and Radiology, Erasmus MC, Rotterdam, The Netherlands; and.
Unlabelled: Peptide receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled somatostatin receptor (SSTR) agonists are successfully used in the clinic for imaging and treatment of neuroendocrine tumors. Contrary to the paradigm that internalization and the resulting accumulation of radiotracers in cells is necessary for efficient tumor targeting, recent studies have demonstrated the superiority of radiolabeled SSTR antagonists for imaging purposes, despite little to no internalization in cells. However, studies comparing the therapeutic antitumor effects of radiolabeled SSTR agonists versus antagonists are lacking.
View Article and Find Full Text PDFDynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
J Nucl Med
December 2010
Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Unlabelled: High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with β-particle-emitting radiolabeled somatostatin analogs will lead to renal failure several months after treatment, urging the coinfusion of the cationic amino acids lysine and arginine to reduce the renal radiation dose. In rat PRRT studies, renal protection by the coadministration of lysine was confirmed by histologic examination of kidney specimens indicating nephrotoxicity. In the current study, we investigated dedicated small-animal SPECT/CT renal imaging in rats to monitor renal function in vivo during follow-up of PRRT, with and without lysine.
View Article and Find Full Text PDFOn the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
Appl Radiat Isot
March 2007
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai-400085, India.
177Lu could be produced with a specific activity of approximately 23,000 mCi/mg (850GBq/mg) by neutron activation using enriched 176Lu (64.3%) target when irradiation was carried out at a thermal neutron flux of 1 x 10(14) n/cm(2)/s for 21 d. 177Lu-DOTA-TATE could be prepared in high radiochemical yield (approximately 99%) and adequate stability using the 177Lu produced indigenously.
View Article and Find Full Text PDFDoes 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?
Nat Clin Pract Endocrinol Metab
November 2005
University Hospital Basel, Switzerland.
Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
Cancer Biother Radiopharm
August 2003
Department of Radiation Physics, Lundberg Laboratory for Cancer Research, Göteborg University, Sahlgrenska University Hospital, Göteborg, Sweden.
Unlabelled: In this study the biodistribution of a somatostatin analogue, (177)Lu-[DOTA(0),Tyr(3)]octreotate, was investigated in an animal model, as a possible therapeutic radiopharmaceutical.
Methods: (177)Lu-[DOTA(0),Tyr(3)]octreotate was injected i.v.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!